# randOmized stUdy Using acceleromeTry to Compare Sacubitril/valsarTan and Enalapril in Patients With Heart Failure

> **NCT02900378** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 621 (actual)

## Conditions studied

- Chronic Heart Failure With Reduced Ejection Fraction

## Interventions

- **DRUG:** LCZ696 (Sacubitril/Valsartan)
- **DRUG:** Placebo of LCZ696 (Sacubitril/Valsartan)
- **DRUG:** Enalapril
- **DRUG:** Placebo of Enalapril

## Key facts

- **NCT ID:** NCT02900378
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-20
- **Primary completion:** 2018-04-11
- **Final completion:** 2018-04-11
- **Target enrollment:** 621 (ACTUAL)
- **Last updated:** 2020-09-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02900378

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02900378, "randOmized stUdy Using acceleromeTry to Compare Sacubitril/valsarTan and Enalapril in Patients With Heart Failure". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02900378. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*